High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival

European Journal of Cancer Part A

Volumn 33, Issue 6, 1997, Pages 926-930

  Dietrich, A ^a   Tanczos, E ^a   Vanscheidt, W ^a   Schopf E ^a   Simon, J C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CD44; Melanoma; Metastasis; Prognostic factors

Indexed keywords

HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL SURFACE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, CD44; ANTIGENS, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0030790353     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00512-6     Document Type: Article

References (28)

1. Lesley J, Hyman R, Kincade P. CD44 and its interaction with the extracellular matrix. Adv Immunol 1993, 54, 271-335.
2. Günthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993, 184, 47-63.
3. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992, 89, 12160-12164.
4. Tölg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993, 21, 1225-1229.
5. Herrlich P, Zöller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993, 14, 395-399.
6. Cooper DL, Dougherty GJ. To metastasize of not? Selection of CD44 splice sites. Nature Medicine 1995, 1, 635-637.
7. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 1994, 6, 726-733.
8. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61, 1303-1313.
9. Herrlich P, Rudy P, Hofmann M, et al. CD44 and splice variants of CD44 in normal differentiation and tumor progression. In Hemler ME, Mihich E, eds. Cell Adhesion Molecules. New York, Plenum Press, 1994, 265-288.
10. East JA, Hart IR. CD44 and its role in tumour progression and metastasis. Eur J Cancer 1993, 29A, 1921-1922.
11. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 1991, 51, 6660-6667.
12. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumour development. J Exp Med 1994, 180, 53-66.
13. Barnhill RL, Mihm MC. Histopathology of malignant melanoma and its precursor lesions. In Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous Melanoma, 2nd edn., Philadelphia, PA, J.B. Lippincott, 1992, 234-264.
14. Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C. Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Hautarzt 1994, 45, 285-291.
15. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
16. Dixon W, Brown M, Engelman L, Hill M, Jennrich R. BMDP Statistical Software. University of California Press, 1990.
17. Manten-Horst E, Danen EH, Smit L, et al. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumour progression and metastatic potential. Int J Cancer 1995, 64, 182-188.
18. Simon JC, Heider KH, Dietrich A, et al. Expression of CD44 isoforms in human skin cancer. Eur J Cancer 1996, 32A, 1394-1400.
19. Danen EJH, ten Berge PJM, van Muijen GNP, Jager MJ, Ruiter DJ. Expression of CD44 and the pattern of CD44 alternative splicing in uveal melanoma. Melanoma Res 1996, 6, 31-35.
20. East JA, Mitchell SD, Hart IR. Expression and function of the CD44 glycoprotein in melanoma cell lines. Melanoma Res 1993, 3, 341-346.
21. Jalkanen S, Joensuu H, Söderström K-O, Klemi P. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 1991, 87, 1835-1840.
22. Horst E, Meijer CJLM, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JHJM, Pals ST. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990, 4, 595-599.
23. Pals ST, Horst E, Ossekoppele GJ, Figdor CG, Scheper RJ, Meijer CJLM. Expression of lymphocyte homing receptor as a mechanism of dissemination of non-Hodgkins's lymphoma. Blood 1989, 73, 885-888.
24. Toole BP, Biswas C, Gross J. Hyaluronate and invasiveness of the rabbit V2 carcinoma. Proc Natl Acad Sci USA 1979, 76, 6299-6303.
25. Moretti S, Martini L, Berti E, Prinzi C, Gianotti B. Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res 1993, 3, 235-239.
26. Knudson W, Biswas C, Toole BP. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Cell 1984, 81, 6767-6771.
27. Zahalka MA, Okon E, Gosslar U, Holzmann B, Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44-and hyaluronate-dependent. J Immunol 1995, 154, 5345-5355.
28. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44 regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992, 118, 971-977.